Business
Financial Statements to 31 December 2023
Financial Statements to 31 December 2023.
About this update from Ethtry Plc
[{"type":"text","content":"\n\n \n \n\n\n\n\nFinancial Statements for the Year Ended 31 December 2023 \nIgraine Plc(“Igraine” or “the Company”)Financial Statements for the Year Ended 31 December 2023 The directors present their strategic report for the year ended 31 December 2023.PRINCIPAL ACTIVITIESIgraine is an investment issuer listed on the Access Segment of the Aquis Growth Market Exchange. The Company maintains an investment strategy focused on the evaluation of innovative technologies and commercially attractive discoveries in the health, medtech, biotech and life science sectors worldwide.The commercial objective of the Company is to seek investment opportunities that are at inflection points that if proven and successful can dramatically alter their valuation and growth trajectory. The Company can identify these opportunities through the network the Board maintains internally and through the advisory services the company retains.REVIEW OF BUSINESSDuring the financial year ended 31 December 2023, Igraine Plc faced a challenging market environment, reflecting broader economic uncertainties and volatility in the small cap space within the UK. Despite these headwinds, the Company remained committed to its strategic objectives and has made notable progress in key areas. In the past year, Igraine Plc successfully made a strategic investment into Fixit Medical Ltd, demonstrating our commitment to identifying and supporting promising opportunities within the healthcare sector. This investment aligns with our long-term strategy to diversify and strengthen our portfolio.Whilst monitoring existing investments and reviewing new targets, the Company has been in discussions with a number of parties regarding a potential full business amalgamation. Discussions held during the year were positive and would significantly assist in creating greater shareholder value. As we move into 2024, these discussions are ongoing and progressing well, reflecting our proactive approach to exploring opportunities that can enhance our strategic position and drive growth.We are also pleased to welcome a new significant shareholder to Igraine Plc. The support from our shareholders is invaluable, and we remain dedicated to delivering value to them.INVESTEE COMPANY UPDATES Fixit Medical LtdDuring the financial period Igraine acquired 20% of Fixit Medical Limited, 343 new Ordinary sha...